Although many treatments have been applied to treat hormone-refractory prostate cancer (HRPC), therapeutic outcome is not altogether satisfactory.
In the case of locally recurring HRPC, uncontrolled gross hematuria, dysuria, and scalding are often experienced. We report a patient who improved following intra-arterial infusion of cisplatin (CDDP) and ifosfamide (IFM) to treat urinary retention caused by locally recurring HRPC. After chemotherapy, cancer volume was remarkably reduced and symptoms improved.
Written by:
Uemura K, Nishihara K, Hayashi T, Tomiyasu K, Matsuoka K. Are you the author?
Department of Urology, Kurume University School of Medicine, Asahimach 67, Kurume, Fukuoka, Japan.
Reference: J Infect Chemother. 2011 Dec 28. Epub ahead of print.
doi: 10.1007/s10156-011-0352-9
PubMed Abstract
PMID: 22203121
UroToday.com Prostate Cancer Section
